Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-22-015010
Filing Date
2022-04-21
Accepted
2022-04-21 08:30:43
Documents
4
Period of Report
2022-06-07

Document Format Files

Seq Description Document Type Size
1 DEF 14A agle-def14a_20220421.htm DEF 14A 944417
2 GRAPHIC g5vlxe23fjkp000002.jpg GRAPHIC 489479
3 GRAPHIC g5vlxe23fjkp000003.jpg GRAPHIC 283100
4 GRAPHIC g5vlxe23fjkp000001.jpg GRAPHIC 7541
  Complete submission text file 0001564590-22-015010.txt   2019293
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37722 | Film No.: 22839739
SIC: 2834 Pharmaceutical Preparations